<DOC>
	<DOCNO>NCT01894022</DOCNO>
	<brief_summary>This open label , long term extension Study AMB115811 . All subject may remain extension study minimum 18 month . Beyond 18-month period , subject may continue extension study one following : - The product approve locally use inoperable CTEPH patient ; - Development use CTEPH population discontinue product approve local regulatory authority - The investigator decide discontinue subject subject decides discontinue study . The primary purpose study provide clinically relevant information long term safety ambrisentan subject inoperable CTEPH .</brief_summary>
	<brief_title>A Open Label Study Assess Long-term Safety , Tolerability Efficacy Ambrisentan Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension ( CTEPH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>Have randomize protocol AMB115811 meet one following : Completed Week 16 visit AMB115811 ; Or Prematurely withdrew AMB115811 whatever reason ( investigational product [ IP ] stop due safety efficacy reason , subject may still enter open label study regardless treatment receive [ treatment supply sponsor ] . The investigator decide whether subject receive IP Subject able willing give write informed consent . As part consent , female subject childbearing potential inform risk teratogenicity need counsel developmentally appropriate manner importance pregnancy prevention ; male subject need inform potential risk testicular tubular atrophy aspermia . Specific information regard warning , precaution , contraindication , adverse event , pertinent information GSK investigational product study treatment may impact subject eligibility provide Investigators Brochure product label PAH indication . In France , subject eligible inclusion study either affiliate beneficiary social security category Subject meeting follow criterion must receive ambrisentan , however may still followedup part study treat accord best clinical practice decide investigator : Subject know hypersensitivity Investigational Products , metabolites , formulation excipients Female subject pregnant breastfeeding nolonger agree comply use effective contraception define protocol . Subjects alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; = 3x Upper limit normal ( ULN ) Subjects bilirubin &gt; = 2xULN ( &gt; 35 % direct bilirubin ) Subjects severe renal impairment ( estimate creatinine clearance &lt; 30 millilitre per minute ( mL/min ) assess within previous 45 day ) point transition Study AMB115811 Subject moderate severe hepatic impairment ( ChildPugh class BC without cirrhosis ) point transition study AMB115811 Subject clinically significant fluid retention opinion investigator Subject clinically significant anemia opinion investigator Subjects enter another clinical trial treat another investigational product exit Study AMB115811 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Inoperable chronic thromboembolic pulmonary hypertension , endothelin receptor antagonist</keyword>
</DOC>